141 related articles for article (PubMed ID: 25292262)
1. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.
Soysal T; Eskazan AE; Ar MC
Expert Rev Hematol; 2014 Dec; 7(6):697-9. PubMed ID: 25292262
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Eskazan AE; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Lymphoma; 2014 Dec; 55(12):2935-7. PubMed ID: 24650055
[No Abstract] [Full Text] [Related]
3. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
Conti RM; Padula WV; Larson RA
Ann Hematol; 2015 Apr; 94 Suppl 2(0 2):S249-57. PubMed ID: 25814091
[TBL] [Abstract][Full Text] [Related]
4. Generic imatinib in the treatment of chronic myeloid leukemia: Cerrahpaşa experience.
Eskazan AE; Soysal T
J Oncol Pharm Pract; 2016 Apr; 22(2):382-4. PubMed ID: 25644376
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Taylor MJ; Scuffham PA
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
[TBL] [Abstract][Full Text] [Related]
6. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
7. Targeted cancer therapy: from bench to bedside to patient.
Gellad WF
J Clin Oncol; 2014 Feb; 32(4):268-70. PubMed ID: 24366939
[No Abstract] [Full Text] [Related]
8. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
Goldman J
Nat Clin Pract Oncol; 2005 Mar; 2(3):126-7. PubMed ID: 16264901
[No Abstract] [Full Text] [Related]
9. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Murphy M; Close J; Lottenberg R; Rajasekhar A
Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
[No Abstract] [Full Text] [Related]
10. Imatinib for chronic myeloid leukaemia: a NICE mess.
Barbour V
Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
[No Abstract] [Full Text] [Related]
11. Position paper on imatinib mesylate in chronic myeloid leukaemia.
O'Brien SG; Rule SA
Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
[No Abstract] [Full Text] [Related]
12. Imatinib for chronic myeloid leukaemia: a NICE mess.
Rajaratnam G; Edwards J
Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
[TBL] [Abstract][Full Text] [Related]
14. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Shih YT; Cortes JE; Kantarjian HM
Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
Garside R; Round A; Dalziel K; Stein K; Royle P
Health Technol Assess; 2002; 6(33):1-162. PubMed ID: 12633529
[No Abstract] [Full Text] [Related]
16. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.
Erba HP
Am J Hematol; 2015 Mar; 90(3):242-9. PubMed ID: 25410137
[TBL] [Abstract][Full Text] [Related]
17. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
18. Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
Breccia M; Salaroli A; Serrao A; Zacheo I; Saracino R; Alimena G
Leuk Lymphoma; 2014 Jan; 55(1):204-6. PubMed ID: 23586870
[No Abstract] [Full Text] [Related]
19. Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.
Moser O; Krumbholz M; Thiede C; Tauer JT; Janz I; Lauten M; Dilloo D; Metzler M; Suttorp M
Pediatr Blood Cancer; 2014 Nov; 61(11):2080-2. PubMed ID: 24810322
[TBL] [Abstract][Full Text] [Related]
20. Imatinib for chronic myeloid leukaemia: a NICE mess.
O'Brien SG
Lancet; 2001 Dec; 358(9296):1902-3. PubMed ID: 11741654
[No Abstract] [Full Text] [Related]
[Next] [New Search]
